Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma

Abstract

This study was aimed to characterize clinicopathological features and prognosis of patients with adenosquamous lung carcinoma (ASC). Among the 2531 patients with lung cancer who underwent surgery between January 2000 and June 2012 in our hospital, 59 were histologically diagnosed as having ASC. The clinicopathological features and follow-up data of ASC patients were collected and analyzed statistically. Superior lobectomy was accomplished in 40 patients, middle and inferior lobectomy in 3, lobectomy plus partial resection of contralateral lung in 5, partial lung resection in 4, and pneumonectomy in 7. Moreover, 22 cases were found to be adenocarcinoma-predominant, and 18 to be squamous cell carcinoma-predominant. The median survival time was 13.6 months, and the 1-, 3-, and 5-year survival rates were 59.9%, 36.4% and 31.2%, respectively. Of the 52 cases with tissue specimens available, 11 had an EGFR mutation (21.2%) and 2 had a KRAS mutation (3.8%). Multivariate analysis showed that histology subtype, pleural invasion, TNM stage, and postoperative treatment were all independent prognostic factors. The data from the current study demonstrated that SCC-predominant histology represents a better prognosis of ASC. Histology subtype, pleural invasion, TNM stage, and postoperative treatment are independent prognostic factors for ASC and adjuvant therapy may help control the disease.

Tumor Location and Survival Outcomes in Lung Adenosquamous Carcinoma: A Propensity Score Matched Analysis

“…LASC, with balanced adenomatous and squamous components, was associated with better survival outcomes than those with one predominant component [9,17]. However, in contrast to these results, some authors also observed that SCC-predominant histology represents a better prognosis of ASC [18]. Therefore, further research on this topic is warranted.…”

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

“…Adenosquamous (ADSCC) disease accounts for 2–3% of all diagnoses, though this diagnosis can only be made with wedge biopsy or tumour resection, which could lead to underestimation of its prevalence in patient populations34. ADSCC is a particularly poor prognosis tumour type56, and genetic studies have demonstrated that both histological components share mutations, suggesting a monoclonal tumour origin7. Notably, in many cases of disease progression after targeted therapy for EGFR mutation, when it is clinically justifiable to take a second biopsy, conversion of ADC to SCC has been observed8.…”

Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma

“…A previous study found that the amount of adenocarcinoma components did not affect the survival rate, while another reported that adenocarcinoma predominant tumors were considered to be a worse prognostic factor [ 18 - 20 ]. Conversely, Gawrychowski et al observed that a balance of squamous and adenocarcinoma components had better prognosis than either being predominant [ 17 ].…”